Biotech Acquisition Company (BIOTU)

Anjalee Khemlani joins Brian Sozzi and Seana Smith to break down the new developments arising around COVID, including Dr. Anthony Fauci defending the administration’s decision to recommend booster shots for vaccinated people and Moderna asking the FDA to allow the use of a third booster dose of its COVID-19 vaccine.

A look at the shareholders of Biotech Acquisition Company ( NASDAQ:BIOT ) can tell us which group is most powerful...

Anjalee Khemlani joins Myles Udland and Brian Sozzi to discuss the World Health Organization’s push to prioritize the COVAX initiative that seeks to vaccinate 10% of the world’s population and its campaign to request nations to implement a moratorium on COVID vaccine boosters.

Biotech Acquisition Company (NASDAQ: BIOTU) (the "Company") announced that, commencing March 18, 2021, holders of the units sold in the Company's initial public offering may elect to separately trade the Company's Class A ordinary shares ("Class A Ordinary Shares") and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A Ordinary Shares and warrants that are separated will trade on the NASDAQ Capital Market under the symbols "BIOT" and "BIOTW," respectively. Those units not separated will continue to trade on the NASDAQ Capital Market under the symbol "BIOTU." Holders of the units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate their units into Class A Ordinary Shares and Warrants.